Antidepressants should come with the nation’s strongest warning in a black box on the label that they can sometimes spur suicidal behavior in children and teenagers, the government’s scientific advisers decided Tuesday.
It’s a rare risk, and therefore families need detailed information on how to balance that concern with the need to treat depression, which itself can lead to suicide, cautioned advisers to the Food and Drug Administration.
So antidepressants prescribed to minors also should come with an easy-to-read pamphlet that explains how to decide if the child is an appropriate candidate and what are the warning signs of suicide, the panel concluded. Also, FDA should consider the extra step of making parents sign a form that they understand the risks before the child receives the first pill.
There may be a backlash to such strong warnings, cautioned FDA advisory committee chairman Dr. Wayne Goodman, psychiatry chairman at the University of Florida.
“It will make prescribing more difficult. I anticipate there will be alarm from parents and the child,” said Goodman, who still backed the step on a 15-8 vote. “I think that’s worth that complication, because it will raise the threshold to prescribing” these drugs to minors.
The drugs seem to help some desperately ill children even though only one, Prozac, has won FDA approval as effective for pediatric depression, said panelist Jean Bronstein, a California nurse who opposed the black-box warning.
“The biggest message I heard from the consumer is they want to be warned about what the risk is,” she said, referring to hours of emotional testimony Monday from families who blamed their children’s suicides on drugs they didn’t know might be risky.
Tearful families greeted Tuesday’s decision with applause.
The FDA isn’t bound by its advisers’ recommendations but usually follows them. FDA drug chief Dr. Robert Temple said a decision could come within months but noted the advisers weren’t unanimous: “When the decision is divided, it’s less of a sure thing.”
The FDA for months called any link with suicidal worsening unproven, but its latest analysis marks a sharp reversal: For every 100 youths given an anti-depressant, two or three may display increased suicidal thoughts or behavior due to the drug.
The controversy erupted last year, when British health authorities declared that most popular antidepressants might sometimes increase the risk of suicidal behavior in children and teenagers. They declared all but one Prozac unsuitable for depressed youth, but stopped short of a ban.
The FDA stresses that 24 studies of 4,000 youths found none who killed themselves.
Still, in March, the FDA strengthened anti-depressant labels to urge close monitoring of patients for suicide warning signs, including increased agitation or hostility, especially when they first start the pills or change a dose.
It called this week’s two-day meeting to see what other safety changes are needed.
Only Prozac has won FDA approval that it truly eases depression in youth. While it is legal for doctors to prescribe adult drugs for children anyway youths account for 7 percent of anti-depressant prescriptions even a rare side effect raises more concern if the drug brings no benefit.
Still, other antidepressants shouldn’t be banned for children, FDA’s advisers stressed. About 10 percent of youths suffer from depression. The illness itself carries a 15 percent risk of suicide if untreated, said Dr. Matthew Rudorfer of the National Institute of Mental Health.
And Prozac doesn’t work for everyone, noted University of Mississippi pharmacist Barbara Wells. Those children “certainly deserve to have access to other drugs.”
Some studies suggest a greater risk for certain drugs, such as Effexor, and initial worries about antidepressants focused on a newer drug family called SSRIs.
“We are unable to conclude that any single agent is free from risk at this time,” the advisers voted unanimously, urging that new warnings cover all pediatric anti-depressant use. That’s because studies of the issue so far are small and flawed.
The suicide risk can occur not only when anti-depressants are prescribed for depressed youth but for other conditions, too, such as obsessive-compulsive disorder, Goodman added.
A black-box warning would make a huge difference in alerting patients to risks, said Kathleen Bodnar, whose 21-year-old daughter killed herself last March while taking Celexa. She had switched to that drug from a liver-damaging competitor more than a year earlier, when “she demanded that her doctor give her something safe.”
The drug industry said Tuesday it supports stronger warnings but wouldn’t comment on the black-box step, which it often opposes.